Massachusetts-based VBI Vaccines Inc. recently announced that Phase 3 study results of its prophylactic 3-antigen hepatitis B (HBV) vaccine candidate were published in The JAMA Network Open.
The CONSTANT study was designed to demonstrate manufacturing equivalence of three lots of VBI’s HBV vaccine candidate and evaluate the immunogenicity of VBI’s 3-antigen HBV vaccine candidate compared to a single-antigen HBV vaccine, Engerix-B®, after two and three doses, and safety and reactogenicity.
Three Antigen Hepatitis B Vaccine Found Effective
Short Hospital Stays for Births More Common During Pandemic
No increase seen in infant rehospitalizations within seven days after earlier discharge to home for healthy, term infants
Cases of Takotsubo Syndrome Up in Middle-Aged, Older Women
Majority of cases (88.3 percent) seen in women, especially those aged 50 years or older; incidence higher in middle-aged men than younger men
More Than Half of COVID-19 Survivors Have Postacute Sequelae
Most common sequelae include functional mobility impairments, pulmonary abnormalities, and mental health disorders
FDA Eases Access to Cheaper Over-the-Counter Hearing Aids
Proposal would create a category of hearing aids that could be sold directly to consumers, without medical exam or audiologist fitting
FDA Expected to Allow Mix ‘n’ Match COVID-19 Vaccines
Agency will not recommend one vaccine over another but may say it is preferable to use same booster as the vaccine